Financial Performance - The group recorded a revenue of RMB 2,398,680,000 for the six months ended June 30, 2023, representing a 32.1% increase compared to the same period last year[2]. - Net profit for the period was RMB 491,465,000, reflecting a 48.4% increase year-on-year[2]. - Earnings per share rose to RMB 0.65, an increase of 47.7% compared to the same period last year[2]. - The gross profit margin improved to 75.2%, up from 73.0% in the previous year[2]. - The group achieved a revenue increase of 32.1% in the first six months of 2023, with injection products generating RMB 957,253,000, up 37.3%[18]. - The net profit attributable to the company's owners for the six months ended June 30, 2023, was RMB 491,465,000, representing a 48.4% increase from RMB 331,123,000 in the same period of 2022[46]. - Revenue for the first half of 2023 reached RMB 2,398,680,000, up from RMB 1,815,194,000 in the same period of 2022, reflecting a significant growth in sales[33]. Sales Performance - Sales of essential medicines included in the national essential drug list increased by 57.0% to RMB 928,912,000, accounting for 38.7% of total sales[5]. - Prescription drug sales grew by 27.2%, with a total sales amount of RMB 2,056,849,000, representing 85.7% of total sales[7]. - Oral product sales increased by 28.9%, driven by exclusive oral products such as specific capsules and granules[4]. - The sales of traditional Chinese medicine formula granules increased significantly by 34.0%, accounting for 26.2% of the total sales of the company[9]. - The sales revenue of respiratory prescription drugs surged by 82.0%, reaching RMB 512,898,000, which represents 21.4% of the company's overall sales[10]. - The sales of the Qingkailing injection reached RMB 400,632,000, up 92.8%, contributing 16.7% to the total sales[10]. - The overall sales of the company's injectable products rose by 37.3%, with significant growth in cardiovascular injectable drugs, which increased by 13.3% to RMB 498,150,000[11]. - The sales of the company's OTC products grew by 72.6%, with the Huoxiang Zhengqi soft capsule and Qingkailing soft capsule increasing by 110.8% and 54.6%, respectively[13]. Cost and Expenses - The overall sales and distribution costs increased by only 24.3%, while administrative expenses rose by 8.1%, contributing to an increase in net profit margin from 18.2% to 20.5%[3]. - The sales cost for the first six months of 2023 was RMB 594,723,000, representing 24.8% of the total revenue[19]. - The sales and distribution costs increased by 24.3% year-on-year, accounting for 42.7% of total revenue, down from 45.4% in the previous year[25]. - Administrative expenses rose by approximately 8.1% year-on-year, representing 5.8% of total revenue, compared to 7.0% in the same period last year[26]. - Research and development costs accounted for 2.0% of total revenue in the first half of 2023, up from 1.6% in the same period of 2022[27]. Dividends and Equity - The group declared an interim dividend of RMB 0.11 per share for the fiscal year 2023[2]. - The company declared an interim dividend of RMB 0.31 per share for 2023, compared to RMB 0.21 per share for 2022, reflecting a 47.6% increase[46]. - The company’s total equity as of June 30, 2023, was RMB 6,639,817,000, an increase of 4.0% from RMB 6,382,526,000 at the end of 2022[36]. Government Support and Grants - The group received government subsidies amounting to RMB 8,812,000, an increase from RMB 7,634,000 in the previous year[21]. - The company received government grants totaling RMB 8,812,000 during the period, compared to RMB 7,634,000 in the previous year[44]. Research and Development - The group is currently conducting clinical trials for three exclusive innovative drugs, including "Sailuotong Capsules" in Phase III trials[15]. - The group submitted new drug applications for two ancient classic formulas, "Shaoyao Gancao Decoction Granules" and "Yiguan Decoction Granules" during the reporting period[16]. - The group plans to accelerate the registration applications for multiple classic formulas by the end of 2023[16]. Market Development - The company has completed the listing of traditional Chinese medicine formula granules in 13 provinces and municipalities, with plans to accelerate market development in key regions[9]. - The company aims to enhance its exclusive oral prescription products through evidence-based medical research and increased academic promotion[12]. - The company has successfully bid for multiple traditional Chinese medicine injections in national and provincial centralized procurement, indicating a recovery in demand[12]. - The company is positioned to benefit from the aging population, which is expected to increase the demand for cardiovascular injectable drugs[12]. Financial Position - As of June 30, 2023, the company had cash and bank balances of approximately RMB 5,364,576,000, an increase from RMB 5,046,495,000 at the end of 2022[29]. - The impairment losses on financial assets increased to RMB 6,236,000 in the first half of 2023, compared to a reversal of RMB 1,443,000 in the same period of 2022[33]. - Trade receivables, net of expected credit loss provisions, increased to RMB 759,323,000 as of June 30, 2023, compared to RMB 673,380,000 as of December 31, 2022[51]. - Trade payables amounted to RMB 387,013,000 as of June 30, 2023, up from RMB 308,745,000 as of December 31, 2022[55]. - The total amount of notes received was RMB 451,773,000 as of June 30, 2023, compared to RMB 301,682,000 as of December 31, 2022[53]. Corporate Governance - The company has adhered to the corporate governance code as per the Hong Kong Stock Exchange rules, with a noted deviation regarding the separation of roles between the Chairman and the CEO, which is currently held by the same individual[67]. - The audit committee has reviewed the accounting principles and policies adopted by the group for the six months ended June 30, 2023[69]. - The interim report for the six months ended June 30, 2023, will be distributed to shareholders and published on the Hong Kong Stock Exchange website and the company's website[69].

Financial Performance - The company's total sales revenue for 2022 reached RMB 3.956 billion, representing a 22.6% increase compared to the previous year[6]. - The gross profit for 2022 was RMB 2.938 billion, with a gross margin improvement reflected in the overall financial performance[6]. - The net profit attributable to shareholders increased by 29.7% year-on-year to RMB 722.773 million[6]. - The company's total sales for 2022 reached RMB 3,950,636,000, representing a 22.6% increase compared to the previous year, with net profit rising by 29.8% to RMB 722,773,000[12]. - The gross profit margin for the year was 74.4%, slightly down from 74.8% in the previous year, while the net profit margin improved from 17.3% to 18.3%[12]. - The overall gross profit margin for the group was 74.4% in 2022, slightly down from 74.8% in 2021[27]. - The net profit attributable to the company's owners for 2022 was RMB 722,773,000, a 29.8% increase compared to the previous year[35]. - The company's total comprehensive income for 2022 was RMB 722,773,000, compared to RMB 556,674,000 in 2021, marking an increase of approximately 30%[156]. - Basic earnings per share rose to RMB 0.96, up from RMB 0.74, marking a 30% increase year-over-year[153]. - The company's profit before tax for 2022 was RMB 917,025,000, an increase from RMB 720,103,000 in 2021, representing a growth of approximately 27.4%[158]. Sales and Market Expansion - Sales of traditional Chinese medicine formula granules exceeded RMB 1.1 billion, marking a 59.3% increase and positioning the company among the top five publicly listed firms in this sector[9]. - The company has expanded its market presence, with traditional Chinese medicine formula granules now available in 2 municipalities and 13 provinces by the end of 2022[9]. - The company plans to focus on deepening its market in Hebei, expanding in Yunnan, and developing in four additional provinces in 2023[9]. - The sales of injection products, soft capsules, and granules saw significant increases of 6.3%, 24.5%, and 18.1% respectively during the year[9]. - Sales of traditional Chinese medicine formula granules surged by 59.3%, contributing to 27.9% of total sales, with overall oral product sales accounting for 64.0% of total revenue[14]. - The sales of injection products grew by 6.3% to RMB 1,423,254,000, accounting for 36.0% of total sales, despite a slowdown in growth in the second half of the year[16]. - Sales in grassroots markets surged by 196.0% compared to the previous year, with sales in Hebei province increasing by 49.0% and in Yunnan province by 84.0%[17]. - The exclusive product "Synovitis Granules" achieved a sales growth of 34.1%, reaching RMB 231,012,000 in 2022[19]. - "Qi Huang Tong Mi Soft Capsules" recorded a sales growth of 45.8%, totaling RMB 68,359,000 in 2022[20]. - "Cholesterol-Lowering Soft Capsules" saw an impressive sales growth of 82.8%, reaching RMB 35,904,000 in 2022[20]. - "Dan Deng Tong Nao Soft Capsules" achieved a sales growth of 71.9%, totaling RMB 31,088,000 in 2022[20]. Research and Development - The company is actively enhancing evidence-based medical research and academic promotion to support its product offerings[9]. - The company has a strong research team of 48 personnel at the Shenwei Drug Research Institute, focusing on innovative drug development, with three proprietary drugs currently in Phase III clinical trials[22]. - The global dementia patient population is expected to double every 20 years, reaching 67.7 million by 2030, with vascular dementia accounting for 32% of cases, highlighting the potential market for the company's innovative drug, Seluotong capsules[22]. - The Q-B-Q-F concentrated pill is entering Phase III clinical trials, targeting mycoplasma pneumonia, which accounts for 30% of pneumonia cases and is prevalent in children[23]. - The company aims to complete the registration of its first batch of classic Chinese medicine formulas by the end of 2023, in line with national policies supporting traditional Chinese medicine[24]. - The company is committed to investing in the research and development of new drugs to diversify its product portfolio[56]. Financial Position and Cash Flow - The company generated a net cash flow from operating activities of RMB 1,109,676,000, with no bank debt reported, resulting in a free cash flow of approximately RMB 980,213,000, equivalent to RMB 1.19 per share[12]. - As of December 31, 2022, the group's cash and structured deposits totaled approximately RMB 5,046,495,000, up from RMB 4,205,722,000 in 2021[36]. - The company's cash and cash equivalents reached RMB 5,026,265 thousand, compared to RMB 4,205,722 thousand in the previous year, showing a growth of 19.5%[154]. - The total liabilities increased to RMB 1,665,593 thousand from RMB 1,098,371 thousand, representing a 51.7% rise[155]. - The net assets of the company were RMB 6,382,526 thousand, up from RMB 5,901,481 thousand, indicating a growth of 8.1%[155]. - Operating cash flow generated from operations for 2022 was RMB 1,266,330,000, compared to RMB 847,723,000 in 2021, indicating a significant increase of about 49.3%[158]. - The net cash increase for cash and cash equivalents at the end of 2022 was RMB 814,218,000, up from RMB 269,226,000 in 2021, reflecting a growth of approximately 202.5%[159]. Corporate Governance and Compliance - The company adheres to corporate governance standards and has implemented new policies, including shareholder communication and anti-fraud measures, in compliance with updated regulations[99]. - The board consists of four executive directors, three independent non-executive directors, and one non-executive director as of December 31, 2022[102]. - The company has established mechanisms to ensure the independence of the board, with three out of eight directors being independent non-executive directors, meeting regulatory requirements[103]. - The board held five meetings and one annual general meeting in 2022, with all executive directors attending all meetings[105]. - The company has established four committees: Audit Committee, Remuneration Committee, Nomination Committee, and Corporate Social Responsibility and Sustainability Committee[104]. - The company has adopted a nomination policy for selecting board members, considering diversity in gender, age, and professional experience[126]. - The company has established a Corporate Governance Committee, which is responsible for reviewing governance policies and compliance with legal requirements[131]. Shareholder Information and Dividends - The board declared a first interim dividend of RMB 0.31 per share, with a total dividend related to the 2022 fiscal year amounting to RMB 0.42 per share, representing a payout ratio of 43.8%[12]. - The company declared an interim dividend of RMB 0.31 per share, totaling RMB 234,174,000, based on 827,000,000 issued shares minus 71,600,000 shares held under the share incentive plan[57]. - As of December 31, 2022, the reserves available for distribution to shareholders amounted to RMB 1,023,848,000, an increase from RMB 874,930,000 in 2021[60]. - The company has a significant shareholder, Fu Wei, holding 546,802,990 shares, which represents approximately 66.12% of the total shares[67]. Related Party Transactions - The company entered into a technical service contract with a related party for a total consideration of RMB 14,000,000, effective from November 5, 2019, to November 4, 2024[80]. - The annual rent payable under a land lease contract with a related party is RMB 1,600,000, covering approximately 49,276 square meters of land for a period of three years[81]. - The company has confirmed compliance with the disclosure requirements under the Listing Rules for all related party transactions[89]. Environmental and Social Responsibility - The company has implemented environmental policies to ensure sustainable operations without compromising environmental integrity[52]. - The company made charitable donations totaling RMB 7,220,600 and contributed 78 hours to public welfare activities during the year[96]. - The board emphasizes values such as quality, social responsibility, innovation, respect for life, and sustainable development to guide business activities[100]. Risk Management and Internal Controls - The group has established a risk management and internal control system to ensure effective governance and compliance with laws and regulations[132]. - The internal audit department has assessed the effectiveness and adequacy of the risk management and internal control system, with no significant deficiencies found[133]. - The company has established internal controls to prevent material misstatements in the financial statements due to fraud or error[149].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立有限公司） （股份代號：2877） 二零二二年年度業績公告 及 宣派二零二三年第一次中期股息 中國神威藥業集團有限公司（「本公司」或「神威」）的董事會（「董事會」）欣然提呈本公司及 其附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年度的經審核綜合業績如 下： | --- | --- | |----------|--------------------------------------------------------------| | | | | 財務概要 | | | | 截至二零二二年十二月三十一日止年度，本集團錄得下列經營業績： | | • | 營業額為人民幣 3,950,636,000 元，比去年上升 22.6% ； | | • | 毛利率為 74.4% ，而去年為 74.8% ； | | • | 年度溢利為人民幣 722,773,000 元，比去年上升 29.8 ...

中 國 神 威 藥 業 集 團 有限公 司 (於開曼群島註冊成立之有限公司) 股份代號: 2877 年度報告 2020 引 領現代中藥 推 進健康產業 Stock Code: 2877 (Incorporated in the Cayman Islands with limited liability) 中 國 神 威 藥 業 集 團 有限公 司 ANNUAL REPORT 2020 PROMOTING CHINESE MEDICINE LEADING HEALTH INDUSTRY MODERN Annual Report 2020 年度報告 目錄 2 公司資料 4 財務摘要 5 董事會主席報告 8 管理層討論及分析 21 董事及高級管理層 24 董事會報告 40 公司管治報告 53 審核委員會報告 54 獨立核數師報告 60 財務報表 公司 資料 董事會 執行董事 李振江先生 （主席） 信蘊霞女士 李惠民先生 陳鍾先生 獨立非執行董事 程麗女士 羅國安教授 張振宇先生 非執行董事 周文成先生（於二零二零年十月一日委任） 董事會委員會 審核委員會 張振宇先生 （委員會主席） 程麗女士 羅國安教授 薪酬委員會 ...